TrialEuropean urology2024

Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.

John Nikitas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.